NeoGenomics (NASDAQ:NEO) Q2 results ($M): Revenue: 101.7 (+50.2%); Clinical Services: 89.0 (+49.6%).
Net income: 2.0 (-66.4%); non-GAAP net income: 7.2 (+61.8%); EPS: 0.02 (-71.4%); non-GAAP EPS: 0.07 (+40.0%); non-GAAP EBITDA: 14.9 (+47.5%).
Cash flow ops (6 mo.): 1.4 (-93.3%).
2019 guidance: Revenue: $388M – 402M from $384M – 400M; net income: ($1M) – 3M from ($3M) – 1M; non-GAAP EBITDA: $54M – 58M from $52M – 56M.
Previously: NeoGenomics EPS beats by $0.01, beats on revenue (July 30)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.